AE Wealth Management LLC Purchases 184364 Shares of Kadmon Holdings Inc (NYSE:KDMN)

Millennium Management LLC acquired a new position in Kadmon during the 4th quarter worth approximately $873,000. Marshall Wace LLP raised its …

Kadmon logoAE Wealth Management LLC raised its stake in shares of Kadmon Holdings Inc (NYSE:KDMN) by 52.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 532,855 shares of the company’s stock after buying an additional 184,364 shares during the quarter. AE Wealth Management LLC owned about 0.41% of Kadmon worth $1,098,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of KDMN. Vivo Capital LLC boosted its position in Kadmon by 20.6% during the 1st quarter. Vivo Capital LLC now owns 12,606,605 shares of the company’s stock worth $33,281,000 after acquiring an additional 2,152,060 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Kadmon during the 1st quarter worth approximately $4,397,000. Millennium Management LLC acquired a new position in Kadmon during the 4th quarter worth approximately $873,000. Marshall Wace LLP raised its stake in shares of Kadmon by 343.1% during the 1st quarter. Marshall Wace LLP now owns 147,362 shares of the company’s stock worth $389,000 after purchasing an additional 114,108 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Kadmon by 1.6% during the 4th quarter. BlackRock Inc. now owns 6,874,443 shares of the company’s stock worth $14,299,000 after purchasing an additional 105,874 shares in the last quarter. Institutional investors own 75.58% of the company’s stock.

KDMN opened at $2.41 on Monday. The company has a current ratio of 2.99, a quick ratio of 3.85 and a debt-to-equity ratio of 0.45. The firm has a market cap of $315.01 million, a price-to-earnings ratio of -2.34 and a beta of 2.09. Kadmon Holdings Inc has a 52-week low of $1.63 and a 52-week high of $4.39. The stock’s fifty day moving average is $2.29.

Kadmon (NYSE:KDMN) last posted its earnings results on Monday, August 5th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The firm had revenue of $0.23 million during the quarter, compared to the consensus estimate of $0.46 million. Kadmon had a negative net margin of 3,974.23% and a negative return on equity of 96.96%. As a group, equities analysts anticipate that Kadmon Holdings Inc will post -0.37 EPS for the current year.

A number of brokerages have recently issued reports on KDMN. Zacks Investment Research cut Kadmon from a “buy” rating to a “hold” rating in a research note on Saturday, July 27th. ValuEngine upgraded Kadmon from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Finally, Oppenheimer began coverage on Kadmon in a research note on Wednesday, June 26th. They issued an “outperform” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $7.93.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease.

Further Reading: Outstanding Shares and The Effect on Share Price

Institutional Ownership by Quarter for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kadmon and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Gyroscope Capital Management Group LLC Boosts Stock Holdings in Duke Energy Corp (NYSE …

Gyroscope Capital Management Group LLC increased its stake in shares of Duke Energy Corp (NYSE:DUK) by 13.9% during the 2nd quarter, …

Duke Energy logoGyroscope Capital Management Group LLC increased its stake in shares of Duke Energy Corp (NYSE:DUK) by 13.9% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,304 shares of the utilities provider’s stock after acquiring an additional 525 shares during the period. Gyroscope Capital Management Group LLC’s holdings in Duke Energy were worth $386,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DUK. BlackRock Inc. grew its position in shares of Duke Energy by 2.6% in the first quarter. BlackRock Inc. now owns 49,544,716 shares of the utilities provider’s stock valued at $4,459,023,000 after purchasing an additional 1,274,643 shares during the last quarter. Geode Capital Management LLC grew its position in Duke Energy by 9.2% during the fourth quarter. Geode Capital Management LLC now owns 8,951,045 shares of the utilities provider’s stock worth $771,079,000 after buying an additional 750,534 shares in the last quarter. FMR LLC grew its position in Duke Energy by 41.8% during the fourth quarter. FMR LLC now owns 7,411,128 shares of the utilities provider’s stock worth $639,581,000 after buying an additional 2,186,456 shares in the last quarter. California Public Employees Retirement System grew its position in Duke Energy by 19.7% during the first quarter. California Public Employees Retirement System now owns 4,394,565 shares of the utilities provider’s stock worth $395,511,000 after buying an additional 724,378 shares in the last quarter. Finally, Swiss National Bank grew its position in Duke Energy by 2.8% during the first quarter. Swiss National Bank now owns 3,146,391 shares of the utilities provider’s stock worth $283,175,000 after buying an additional 84,900 shares in the last quarter. Institutional investors and hedge funds own 60.01% of the company’s stock.

In related news, SVP Dwight L. Jacobs sold 1,700 shares of Duke Energy stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $85.92, for a total value of $146,064.00. Following the completion of the transaction, the senior vice president now directly owns 6,091 shares in the company, valued at approximately $523,338.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Lloyd M. Yates sold 5,117 shares of Duke Energy stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $88.20, for a total transaction of $451,319.40. The disclosure for this sale can be found here. Insiders sold a total of 8,598 shares of company stock valued at $752,989 over the last quarter. 0.09% of the stock is owned by company insiders.

A number of equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Duke Energy from a “hold” rating to a “sell” rating and set a $95.00 price target on the stock. in a research report on Wednesday, June 26th. Barclays dropped their price target on Duke Energy from $96.00 to $94.00 and set an “equal weight” rating for the company in a research note on Tuesday, June 18th. Morgan Stanley dropped their price target on Duke Energy from $99.00 to $92.00 and set an “equal weight” rating for the company in a research note on Thursday. Citigroup dropped their price target on Duke Energy from $91.00 to $88.00 and set a “neutral” rating for the company in a research note on Tuesday, July 30th. Finally, KeyCorp began coverage on Duke Energy in a research report on Tuesday, June 4th. They set a “sector weight” rating for the company. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $90.50.

Shares of Duke Energy stock traded up $0.44 during mid-day trading on Friday, hitting $89.75. 1,946,732 shares of the stock were exchanged, compared to its average volume of 2,596,879. Duke Energy Corp has a 12 month low of $78.00 and a 12 month high of $91.67. The firm’s 50-day moving average is $88.59. The company has a quick ratio of 0.49, a current ratio of 0.71 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $65.07 billion, a P/E ratio of 19.01, a P/E/G ratio of 3.69 and a beta of 0.12.

Duke Energy (NYSE:DUK) last posted its quarterly earnings results on Tuesday, August 6th. The utilities provider reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.14. The company had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.76 billion. Duke Energy had a net margin of 13.23% and a return on equity of 8.02%. Duke Energy’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 EPS. On average, research analysts predict that Duke Energy Corp will post 4.93 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Friday, August 16th will be paid a $0.945 dividend. This represents a $3.78 dividend on an annualized basis and a yield of 4.21%. This is a positive change from Duke Energy’s previous quarterly dividend of $0.93. The ex-dividend date is Thursday, August 15th. Duke Energy’s payout ratio is currently 78.60%.

About Duke Energy

Duke Energy Corp. engages in distribution of natural gas and energy related services. It operates through the following segments: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Commercial Renewables. The Electric Utilities and Infrastructure segment conducts operations primarily through the regulated public utilities of Duke Energy Carolinas, Duke Energy Progress, Duke Energy Florida, Duke Energy Indiana and Duke Energy Ohio.

Read More: Elliott Wave Theory

Institutional Ownership by Quarter for Duke Energy (NYSE:DUK)

Receive News & Ratings for Duke Energy Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Duke Energy and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

2793 Shares in Jack Henry & Associates, Inc. (NASDAQ:JKHY) Bought by Gyroscope Capital …

WINTON GROUP Ltd increased its stake in shares of Jack Henry & Associates by 52.2% in the second quarter. WINTON GROUP Ltd now owns 9,521 …

Jack Henry & Associates logoGyroscope Capital Management Group LLC purchased a new stake in Jack Henry & Associates, Inc. (NASDAQ:JKHY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 2,793 shares of the technology company’s stock, valued at approximately $383,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of JKHY. Zions Bancorporation N.A. lifted its holdings in shares of Jack Henry & Associates by 5.1% in the second quarter. Zions Bancorporation N.A. now owns 2,477 shares of the technology company’s stock worth $332,000 after acquiring an additional 120 shares during the last quarter. WINTON GROUP Ltd increased its stake in shares of Jack Henry & Associates by 52.2% in the second quarter. WINTON GROUP Ltd now owns 9,521 shares of the technology company’s stock valued at $1,275,000 after buying an additional 3,266 shares during the period. Cox Capital Mgt LLC increased its stake in shares of Jack Henry & Associates by 1.2% in the second quarter. Cox Capital Mgt LLC now owns 12,977 shares of the technology company’s stock valued at $1,738,000 after buying an additional 156 shares during the period. Amundi Pioneer Asset Management Inc. increased its stake in shares of Jack Henry & Associates by 75.6% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 176,174 shares of the technology company’s stock valued at $24,442,000 after buying an additional 75,870 shares during the period. Finally, FMR LLC increased its stake in shares of Jack Henry & Associates by 44.1% in the first quarter. FMR LLC now owns 317,841 shares of the technology company’s stock valued at $44,097,000 after buying an additional 97,259 shares during the period. Institutional investors and hedge funds own 89.34% of the company’s stock.

Several research firms have recently issued reports on JKHY. Zacks Investment Research raised Jack Henry & Associates from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. BidaskClub raised shares of Jack Henry & Associates from a “hold” rating to a “buy” rating in a research report on Saturday, August 3rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $159.00 target price on shares of Jack Henry & Associates in a research report on Tuesday, May 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $154.25.

In related news, insider Mark S. Forbis sold 501 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $137.58, for a total value of $68,927.58. Following the completion of the sale, the insider now owns 797 shares in the company, valued at approximately $109,651.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew C. Flanigan sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $137.70, for a total value of $688,500.00. Following the completion of the sale, the director now owns 49,226 shares of the company’s stock, valued at approximately $6,778,420.20. The disclosure for this sale can be found here. Insiders have sold a total of 9,221 shares of company stock valued at $1,267,422 in the last ninety days. Insiders own 0.84% of the company’s stock.

JKHY traded down $0.20 during trading hours on Friday, hitting $140.62. The stock had a trading volume of 162,771 shares, compared to its average volume of 380,428. The firm’s fifty day simple moving average is $138.18. Jack Henry & Associates, Inc. has a 1 year low of $120.20 and a 1 year high of $163.68. The stock has a market capitalization of $10.87 billion, a PE ratio of 39.17, a PEG ratio of 3.41 and a beta of 0.91.

Jack Henry & Associates Company Profile

Jack Henry & Associates, Inc provides technology solutions and payment processing services primarily for financial services organizations in the United States. The company offers information and transaction processing solutions for banks ranging from community to multi-billion dollar institutions under the Jack Henry Banking brand; core data processing solutions for various credit unions under the Symitar brand; and specialized financial performance, imaging and payments processing, information security and risk management, retail delivery, and online and mobile solutions to financial institutions and corporate entities under the ProfitStars brand.

Recommended Story: Investing strategies using the yield curve

Institutional Ownership by Quarter for Jack Henry & Associates (NASDAQ:JKHY)

Receive News & Ratings for Jack Henry & Associates Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Jack Henry & Associates and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Bailard Inc. Makes New Investment in Fluent Inc (NASDAQ:FLNT)

Two Sigma Investments LP acquired a new stake in Fluent in the fourth quarter valued at approximately $48,000. Finally, Squarepoint Ops LLC …

Fluent logoBailard Inc. acquired a new position in Fluent Inc (NASDAQ:FLNT) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 30,300 shares of the company’s stock, valued at approximately $163,000.

Several other hedge funds have also recently made changes to their positions in the business. BlackRock Inc. raised its holdings in Fluent by 7.2% in the fourth quarter. BlackRock Inc. now owns 1,797,693 shares of the company’s stock valued at $6,472,000 after acquiring an additional 121,479 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Fluent by 27.2% in the fourth quarter. Bank of New York Mellon Corp now owns 141,004 shares of the company’s stock valued at $507,000 after acquiring an additional 30,162 shares in the last quarter. Geode Capital Management LLC raised its holdings in Fluent by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 429,741 shares of the company’s stock valued at $1,547,000 after acquiring an additional 17,108 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Fluent in the fourth quarter valued at approximately $48,000. Finally, Squarepoint Ops LLC acquired a new stake in Fluent in the fourth quarter valued at approximately $37,000. Institutional investors own 27.36% of the company’s stock.

Several brokerages recently weighed in on FLNT. Roth Capital raised shares of Fluent from a “neutral” rating to a “buy” rating and raised their target price for the company from $5.50 to $8.50 in a report on Thursday, May 9th. Zacks Investment Research cut shares of Fluent from a “buy” rating to a “hold” rating in a report on Monday, July 15th. Barrington Research reaffirmed a “buy” rating and issued a $9.00 target price on shares of Fluent in a report on Wednesday, May 29th. Finally, ValuEngine cut shares of Fluent from a “buy” rating to a “hold” rating in a report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $7.92.

Shares of Fluent stock opened at $3.06 on Friday. The stock has a market capitalization of $377.59 million, a price-to-earnings ratio of 41.00, a P/E/G ratio of 0.65 and a beta of 0.85. Fluent Inc has a 52 week low of $1.95 and a 52 week high of $7.47. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.29 and a quick ratio of 2.29. The company has a 50 day moving average of $5.30.

Fluent (NASDAQ:FLNT) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.01 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.03). The company had revenue of $70.56 million during the quarter, compared to analysts’ expectations of $66.89 million. Fluent had a net margin of 2.87% and a return on equity of 4.54%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.07 earnings per share. As a group, sell-side analysts predict that Fluent Inc will post 0.19 earnings per share for the current year.

Fluent Company Profile

Fluent, Inc provides data-driven digital marketing services primarily in the United States. The company also offers customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. It delivers data and performance-based marketing executions to approximately 500 consumer brands, direct marketers, and agencies across a range of industries, including financial services, retail and consumer, media and entertainment, staffing and recruitment, and marketing services.

See Also: Technical Analysis of Stocks, How Can It Help

Institutional Ownership by Quarter for Fluent (NASDAQ:FLNT)

Receive News & Ratings for Fluent Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fluent and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Cytokinetics, Inc. (NASDAQ:CYTK) Expected to Post Earnings of -$0.49 Per Share

Two Sigma Investments LP boosted its holdings in Cytokinetics by 41.0% in the fourth quarter. Two Sigma Investments LP now owns 45,242 shares of …

Cytokinetics logoWall Street analysts expect Cytokinetics, Inc. (NASDAQ:CYTK) to post earnings per share (EPS) of ($0.49) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cytokinetics’ earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.48). Cytokinetics posted earnings per share of ($0.40) during the same quarter last year, which indicates a negative year-over-year growth rate of 22.5%. The company is expected to issue its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Cytokinetics will report full year earnings of ($1.85) per share for the current financial year, with EPS estimates ranging from ($1.96) to ($1.56). For the next fiscal year, analysts forecast that the company will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.00) to ($1.40). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Cytokinetics.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.06). The company had revenue of $7.14 million during the quarter, compared to analyst estimates of $6.81 million. Cytokinetics had a negative return on equity of 405.45% and a negative net margin of 308.73%.

A number of equities analysts recently commented on the company. Morgan Stanley set a $11.00 price objective on Cytokinetics and gave the stock a “hold” rating in a research note on Monday, July 15th. Zacks Investment Research lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Cytokinetics in a research note on Friday, May 10th. BidaskClub raised shares of Cytokinetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, ValuEngine raised shares of Cytokinetics from a “buy” rating to a “strong-buy” rating in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $15.00.

In other news, CEO Robert I. Blum sold 6,000 shares of Cytokinetics stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $10.94, for a total value of $65,640.00. Following the sale, the chief executive officer now directly owns 256,022 shares in the company, valued at approximately $2,800,880.68. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders sold 16,500 shares of company stock worth $176,535. Corporate insiders own 5.70% of the company’s stock.

Several hedge funds have recently modified their holdings of CYTK. Bank of New York Mellon Corp grew its holdings in shares of Cytokinetics by 1.7% during the fourth quarter. Bank of New York Mellon Corp now owns 591,609 shares of the biopharmaceutical company’s stock worth $3,738,000 after purchasing an additional 10,144 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Cytokinetics by 13.8% in the fourth quarter. Geode Capital Management LLC now owns 585,543 shares of the biopharmaceutical company’s stock valued at $3,700,000 after acquiring an additional 70,954 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Cytokinetics by 41.0% in the fourth quarter. Two Sigma Investments LP now owns 45,242 shares of the biopharmaceutical company’s stock valued at $286,000 after acquiring an additional 13,162 shares during the last quarter. Bank of America Corp DE lifted its stake in Cytokinetics by 303.8% in the fourth quarter. Bank of America Corp DE now owns 43,462 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 32,699 shares during the period. Finally, Squarepoint Ops LLC lifted its stake in Cytokinetics by 14.2% in the fourth quarter. Squarepoint Ops LLC now owns 11,600 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 1,438 shares during the period. Hedge funds and other institutional investors own 69.23% of the company’s stock.

Cytokinetics stock opened at $13.51 on Thursday. The business has a 50 day moving average of $11.60. The company has a debt-to-equity ratio of 12.35, a quick ratio of 7.09 and a current ratio of 7.09. The firm has a market capitalization of $786.74 million, a price-to-earnings ratio of -6.93 and a beta of 1.66. Cytokinetics has a one year low of $5.75 and a one year high of $14.25.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility.

Read More: What is the cash asset ratio?

Get a free copy of the Zacks research report on Cytokinetics (CYTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cytokinetics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts